China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more
Market Cap & Net Worth: China Resources Double-Crane Pharmaceutical Co Ltd (600062)
China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) has a market capitalization of $2.58 Billion (CN¥18.93 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #4315 globally and #425 in its home market, demonstrating a 1.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Resources Double-Crane Pharmaceutical Co Ltd's stock price CN¥18.22 by its total outstanding shares 1038757509 (1.04 Billion).
China Resources Double-Crane Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
China Resources Double-Crane Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.94 Billion to $2.58 Billion (2.88% CAGR).
Index Memberships
China Resources Double-Crane Pharmaceutical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$1.18 Trillion | 0.22% | #89 of 285 |
Weight: China Resources Double-Crane Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
China Resources Double-Crane Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.25x
China Resources Double-Crane Pharmaceutical Co Ltd's market cap is 0.25 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.72x
China Resources Double-Crane Pharmaceutical Co Ltd's market cap is 1.72 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.94 Billion | $5.14 Billion | $661.06 Million | 0.38x | 2.93x |
| 2016 | $1.91 Billion | $5.49 Billion | $714.21 Million | 0.35x | 2.67x |
| 2017 | $2.56 Billion | $6.42 Billion | $842.61 Million | 0.40x | 3.04x |
| 2018 | $1.51 Billion | $8.23 Billion | $968.59 Million | 0.18x | 1.56x |
| 2019 | $1.66 Billion | $9.38 Billion | $1.06 Billion | 0.18x | 1.58x |
| 2020 | $1.56 Billion | $8.50 Billion | $1.01 Billion | 0.18x | 1.56x |
| 2021 | $1.79 Billion | $9.11 Billion | $935.69 Million | 0.20x | 1.91x |
| 2022 | $2.49 Billion | $9.63 Billion | $1.18 Billion | 0.26x | 2.11x |
| 2023 | $2.63 Billion | $11.31 Billion | $1.67 Billion | 0.23x | 1.58x |
| 2024 | $2.80 Billion | $11.21 Billion | $1.63 Billion | 0.25x | 1.72x |
Competitor Companies of 600062 by Market Capitalization
Companies near China Resources Double-Crane Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to China Resources Double-Crane Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
China Resources Double-Crane Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, China Resources Double-Crane Pharmaceutical Co Ltd's market cap moved from $1.94 Billion to $ 2.58 Billion, with a yearly change of 2.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.58 Billion | -0.38% |
| 2025 | CN¥2.59 Billion | -7.63% |
| 2024 | CN¥2.80 Billion | +6.45% |
| 2023 | CN¥2.63 Billion | +5.76% |
| 2022 | CN¥2.49 Billion | +39.26% |
| 2021 | CN¥1.79 Billion | +14.33% |
| 2020 | CN¥1.56 Billion | -6.04% |
| 2019 | CN¥1.66 Billion | +10.28% |
| 2018 | CN¥1.51 Billion | -41.07% |
| 2017 | CN¥2.56 Billion | +34.23% |
| 2016 | CN¥1.91 Billion | -1.63% |
| 2015 | CN¥1.94 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of China Resources Double-Crane Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.58 Billion USD |
| MoneyControl | $2.58 Billion USD |
| MarketWatch | $2.58 Billion USD |
| marketcap.company | $2.58 Billion USD |
| Reuters | $2.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.